215 related articles for article (PubMed ID: 33704812)
21. Idiopathic pulmonary fibrosis lung transplant recipients are at increased risk for EBV-associated posttransplant lymphoproliferative disorder and worse survival.
Iasella CJ; Winters SA; Kois A; Cho J; Hannan SJ; Koshy R; Moore CA; Ensor CR; Lendermon EA; Morrell MR; Pilewski JM; Sanchez PG; Kass DJ; Alder JK; Nouraie SM; McDyer JF
Am J Transplant; 2020 May; 20(5):1439-1446. PubMed ID: 31874120
[TBL] [Abstract][Full Text] [Related]
22. Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder.
Holman CJ; Karger AB; Mullan BD; Brundage RC; Balfour HH
Clin Transplant; 2012; 26(5):741-7. PubMed ID: 22385033
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States.
Tajima T; Martinez OM; Bernstein D; Boyd SD; Gratzinger D; Lum G; Sasaki K; Tan B; Twist CJ; Weinberg K; Armstrong B; Desai DM; Mazariegos GV; Chin C; Fishbein TM; Tekin A; Venick RS; Krams SM; Esquivel CO
Pediatr Transplant; 2024 Jun; 28(4):e14763. PubMed ID: 38682750
[TBL] [Abstract][Full Text] [Related]
24. Combined assessment of Epstein-Barr virus viral capsid antigen and Epstein-Barr virus nuclear antigen-1 serology for post-transplant lymphoproliferative disorder risk stratification in adult solid organ transplant recipients.
Heldman MR; Edlefsen KL; Pepper G; Kapnadak SG; Rakita RM; Fisher CE; Limaye AP
Transpl Infect Dis; 2022 Dec; 24(6):e13933. PubMed ID: 36000190
[TBL] [Abstract][Full Text] [Related]
25. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients.
Smith JM; Corey L; Healey PJ; Davis CL; McDonald RA
Transplantation; 2007 Jun; 83(11):1423-8. PubMed ID: 17565314
[TBL] [Abstract][Full Text] [Related]
26. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
[TBL] [Abstract][Full Text] [Related]
27. Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder.
Kinch A; Sundström C; Tufveson G; Glimelius I
Leuk Lymphoma; 2016 Oct; 57(10):2351-8. PubMed ID: 27104753
[TBL] [Abstract][Full Text] [Related]
28. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
29. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
Front Immunol; 2020; 11():1231. PubMed ID: 32625211
[TBL] [Abstract][Full Text] [Related]
30. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
[TBL] [Abstract][Full Text] [Related]
31. Clinical and virologic outcomes in high-risk adult Epstein-Barr virus mismatched organ transplant recipients.
Kumar D; Patil N; Husain S; Chaparro C; Bhat M; Kim SJ; Humar A
Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28489256
[TBL] [Abstract][Full Text] [Related]
32. The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.
Martinez OM; Krams SM
Transplantation; 2017 Sep; 101(9):2009-2016. PubMed ID: 28376031
[TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting.
Paya CV; Fung JJ; Nalesnik MA; Kieff E; Green M; Gores G; Habermann TM; Wiesner PH; Swinnen JL; Woodle ES; Bromberg JS
Transplantation; 1999 Nov; 68(10):1517-25. PubMed ID: 10589949
[TBL] [Abstract][Full Text] [Related]
34. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.
Zimmermann H; Oschlies I; Fink S; Pott C; Neumayer HH; Lehmkuhl H; Hauser IA; Dreyling M; Kneba M; Gärtner B; Anagnostopoulos I; Riess H; Klapper W; Trappe RU
Transplantation; 2012 Mar; 93(5):543-50. PubMed ID: 22234349
[TBL] [Abstract][Full Text] [Related]
35. Posttransplant lymphoproliferative disorder after liver and kidney transplant.
Akar Özkan E; Özdemir BH; Deniz EE; Tunca MZ; Haberal M
Exp Clin Transplant; 2014 Mar; 12 Suppl 1():142-8. PubMed ID: 24635813
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
[TBL] [Abstract][Full Text] [Related]
37. The biology of Epstein-Barr virus in post-transplant lymphoproliferative disease.
Hsieh WS; Lemas MV; Ambinder RF
Transpl Infect Dis; 1999 Sep; 1(3):204-12. PubMed ID: 11428990
[TBL] [Abstract][Full Text] [Related]
38. Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders.
Afify ZAM; Taj MM; Orjuela-Grimm M; Srivatsa K; Miller TP; Edington HJ; Dalal M; Robles J; Ford JB; Ehrhardt MJ; Ureda TJ; Rubinstein JD; McCormack S; Rivers JM; Chisholm KM; Kavanaugh MK; Bukowinski AJ; Friehling ED; Ford MC; Reddy SN; Marks LJ; Smith CM; Mason CC
Cancer; 2023 Mar; 129(5):780-789. PubMed ID: 36571557
[TBL] [Abstract][Full Text] [Related]
39. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study.
Johnson LR; Nalesnik MA; Swerdlow SH
Am J Surg Pathol; 2006 Dec; 30(12):1604-12. PubMed ID: 17122518
[TBL] [Abstract][Full Text] [Related]
40. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
Mentzer SJ; Perrine SP; Faller DV
Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
